Current status and prospect of selective internal radiotherapy with yttrium-90 for intrahepatic cholangiocarcinoma

doi:10.3877/cma.j.issn.2095-3232.2025027

Abstract

Abstract:

Intrahepatic cholangiocarcinoma （ICC） is the second most common primary liver cancer secondary to hepatocellular carcinoma.Most patients are diagnosed in the middle and late stage and can only receive systematic and local treatments.In recent years， the therapeutic effect of selective internal radiotherapy with yttrium-90 for malignant liver tumors has been widely recognized at home and abroad，and it has become an important local treatment for malignant liver tumors.It’s effectiveness and safety in the treatment of malignant liver tumors have been validated by relevant clinical studies.In this article， the latest literature review of selective internal radiotherapy with yttrium-90 for ICC was conducted， and the safety， effectiveness and practicability of selective internal radiotherapy with yttrium-90 as a single option，combined with chemotherapy， radiation segmentectomy/hepatectomy and liver transplantation for ICC were summarized.

Key words: Yttrium-90, Intrahepatic cholangiocarcinoma, Selective internal radiation therapy

Kangshou Liu, Mingrong Cao, Jian Sun. Current status and prospect of selective internal radiotherapy with yttrium-90 for intrahepatic cholangiocarcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 197-202.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2025027

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2025/V14/I02/197

References 33

［1］	Siegel R， Naishadham D， Jemal A.Cancer statistics， 2013［J］.CA A Cancer J Clin， 2013， 63（1）： 11-30.DOI： 10.3322/caac.21166.
［2］	Beal EW， Tumin D， Moris D， et al.Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma［J］.Hepatobiliary Surg Nutr， 2018， 7（4）： 270-276.DOI： 10.21037/hbsn.2018.03.16.
［3］	Bray F， Ferlay J， Soerjomataram I， et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin， 2018， 68（6）： 394-424.DOI： 10.3322/caac.21492.
［4］	Labib PL， Goodchild G， Pereira SP.Molecular pathogenesis of cholangiocarcinoma［J］.BMC Cancer， 2019， 19（1）： 185.DOI： 10.1186/s12885-019-5391-0.
［5］	Khan SA， Tavolari S， Brandi G.Cholangiocarcinoma： epidemiology and risk factors［J］.Liver Int， 2019， 39（Suppl 1）： 19-31.DOI： 10.1111/liv.14095.
［6］	Welzel TM， Graubard BI， El-Serag HB， et al.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States：a population-based case-control study［J］.Clin Gastroenterol Hepatol，2007， 5（10）： 1221-1228.DOI： 10.1016/j.cgh.2007.05.020.
［7］	Welzel TM， Mellemkjaer L， Gloria G， et al.Risk factors for intrahepatic cholangiocarcinoma in a low-risk population： a nationwide casecontrol study［J］.Int J Cancer， 2007， 120（3）： 638-641.DOI： 10.1002/ijc.22283.
［8］	中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）：胆道恶性肿瘤诊疗指南2023［M］.北京：人民卫生出版社， 2023.Guideline working committee of the Chinese Society of clinical Oncolgy.Chinese Society of Clinical Oncology （csco）： diagnosis and treatment guidelines for biliary maliqnant tumors 2023 ［M］.Beijing：People’s Health Publishing House， 2023.
［9］	Valle J， Wasan H， Palmer DH， et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer［J］.N Engl J Med， 2010， 362（14）：1273-1281.DOI： 10.1056/NEJMoa0908721.
［10］	Oh DY， He AR， Qin S， et al.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer［J］.NEJM Evid， 2022， 1（8）：EVIDoa2200015.DOI： 10.1056/EVIDoa2200015.
［11］	Oh D， He AR， Qin S， et al.Updated overall survival （OS） from the phase III TOPAZ-1 study of durvalumab （D） or placebo （PBO） plus gemcitabine and cisplatin （+ GC） in patients （pts） with advanced biliary tract cancer （BTC）［J］.Ann Oncol， 2022， 33（suppl 7）： 565-S566.DOI： 10.1016/j.annnonc.2022.07.084.
［12］	Hickey RM， Lewandowski RJ， Salem R.Yttrium-90 radioembolization for hepatocellular carcinoma［J］.Semin Nucl Med， 2016，46（2）： 105-108.DOI： 10.1053/j.semnuclmed.2015.10.011.
［13］	Westcott MA， Coldwell DM， Liu DM， et al.The development，commercialization， and clinical context of yttrium-90 radiolabeled resin and glass microspheres［J］.Adv Radiat Oncol， 2016， 1（4）： 351-364.DOI： 10.1016/j.adro.2016.08.003.
［14］	Andrews JC， Walker SC， Ackermann RJ， et al.Hepatic radioembolization with yttrium-90 containing glass microspheres：preliminary results and clinical follow-up［J］.J Nucl Med， 1994，35（10）： 1637-1644.
［15］	Dancey JE， Shepherd FA， Paul K， et al.Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres［J］.J Nucl Med， 2000， 41（10）： 1673-1681.
［16］	Houle S， Yip TK， Shepherd FA， et al.Hepatocellular carcinoma： pilot trial of treatment with Y-90 microspheres［J］.Radiology， 1989， 172（3）：857-860.DOI： 10.1148/radiology.172.3.2549567.
［17］	Fernandez-Ros N， Iñarrairaegui M， Paramo JA， et al.Radioembolization of hepatocellular carcinoma activates liver regeneration，induces inflammation and endothelial stress and activates coagulation［J］.Liver Int， 2015， 35（5）： 1590-1596.DOI： 10.1111/liv.12592.
［18］	Chew V， Lee YH， Pan L， et al.Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma［J］.Gut， 2019， 68（2）： 335-346.DOI： 10.1136/gutjnl-2017-315485.
［19］	Robinson TJ， Du L， Matsuoka L， et al.Survival and toxicities after yttrium-90 transarterial radioembolization of cholangiocarcinoma in the RESiN registry［J］.J Vasc Interv Radiol， 2023， 34（4）： 694-701.e3.DOI： 10.1016/j.jvir.2022.10.042.
［20］	Mosconi C， Cacioppa LM， Cappelli A， et al.Update of the bologna experience in radioembolization of intrahepatic cholangiocarcinoma［J］.Technol Cancer Res Treat， 2023， 22： 15330338231155690.DOI：10.1177/15330338231155690.
［21］	Edeline J， Touchefeu Y， Guiu B， et al.Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma： a phase 2 clinical trial［J］.JAMA Oncol， 2020，6（1）： 51-59.DOI： 10.1001/jamaoncol.2019.3702.
［22］	Chan SL， Chotipanich C， Choo SP， et al.Selective internal radiation therapy with yttrium-90 resin microspheres followed by gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma： a phase 2 single-arm multicenter clinical trial［J］.Liver Cancer， 2022，11（5）： 451-459.DOI： 10.1159/000525489.
［23］	Yu Q， Liu C， Pillai A， et al.Twenty years of radiation therapy of unresectable intrahepatic cholangiocarinoma： internal or external？ A systematic review and meta-analysis［J］.Liver Cancer， 2021， 10（5）：433-450.DOI： 10.1159/000516880.
［24］	Riaz A， Gates VL， Atassi B， et al.Radiation segmentectomy： a novel approach to increase safety and efficacy of radioembolization［J］.Int J Radiat Oncol Biol Phys， 2011， 79（1）： 163-171.DOI： 10.1016/j.ijrobp.2009.10.062.
［25］	Vouche M， Habib A， Ward TJ， et al.Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation：multicenter radiology-pathology correlation and survival of radiation segmentectomy［J］.Hepatology， 2014， 60（1）： 192-201.DOI： 10.1002/hep.27057.
［26］	Paz-Fumagalli R， Core J， Padula C， et al.Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma［J］.Oncotarget， 2021， 12（20）： 2075-2088.DOI： 10.18632/oncotarget.28060.
［27］	Filippi L， Di Costanzo GG， Tortora R， et al.Repeated treatment with ⁹⁰Y-microspheres in intrahepatic cholangiocarcinoma relapsed after the first radioembolization［J］.Cancer Biother Radiopharm， 2019， 34（4）：231-237.DOI： 10.1089/cbr.2018.2718.
［28］	Hand F， Hoti E.Contemporary role of liver transplantation for the treatment of cholangiocarcinoma［J］.Expert Rev Gastroenterol Hepatol，2020， 14（6）： 475-481.DOI： 10.1080/17474124.2020.1765771.
［29］	Sapisochin G， Facciuto M， Rubbia-Brandt L， et al.Liver transplantation for “very early” intrahepatic cholangiocarcinoma： International retrospective study supporting a prospective assessment［J］.Hepatology， 2016， 64（4）： 1178-1188.DOI： 10.1002/hep.28744.
［30］	Lunsford KE， Javle M， Heyne K， et al.Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy： a prospective case-series［J］.Lancet Gastroenterol Hepatol，2018， 3（5）： 337-348.DOI： 10.1016/S2468-1253（18）30045-1.
［31］	Lopez-Lopez V， Miura K， Kuemmerli C， et al.Selecting the appropriate downstaging and bridging therapies for hepatocellular carcinoma： what is the role of transarterial radioembolization？A pooled analysis［J］.Cancers， 2023， 15（7）： 2122.DOI： 10.3390/cancers15072122.
［32］	Gabr A， Kulik L， Mouli S， et al.Liver transplantation following yttrium-90 radioembolization： 15-year experience in 207-patient cohort［J］.Hepatology， 2021， 73（3）： 998-1010.DOI： 10.1002/hep.31318.
［33］	吴添庆，王炯亮，郑梽楷，等.经动脉放疗栓塞术治疗不可切除肝内胆管细胞癌疗效与安全性Meta分析［J/OL］.中华肝脏外科手术学电子杂志，2023，12（2）：190-195.DOI：10.3877/cma.j.issn.2095-3232.2023.02.013.Wu TQ， Wang JL， Zheng ZK， et al.Efffcacy and safety of transarterial radioembolization for unresectable intrahepatic cholangiocarcinoma：a Meta-analysis［J/OL］.Chin J Hepat Surg（Electronic Edition）， 2023，12（2）： 190-195.DOI：10.3877/cma.j.issn.2095-3232.2023.02.013.

[1]	Jinlong Zhou, Junjie Liu, Hao Gu. Prognostic value of lymph node dissection for intrahepatic cholangiocarcinoma: A meta-analysis [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(02): 155-160.
[2]	Yinzhen Pan, Xiuyu Zhang, Yantao Mai, Zhiqiang Liang. Clinical efficacy of two types of operation for intrahepatic cholangiocarcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(02): 208-211.
[3]	Wang Feng, Zhenzhong Ma, Linhua Tang. Clinical study of CT scanning 3D reconstruction in laparoscopic hepatectomy for intrahepatic cholangiocarcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 104-107.
[4]	Jinhua Zhang, Suo Zhao. A comparative study of the near and long term effects of early ICC laparoscopic hepatectomy in different lymph node dissection ranges [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 578-581.
[5]	Xiaolong Huang, Shibu Lin, Lin Han, Youke Chen, Yan Yang. Prognostic study of radical resection of intrahepatic cholangiocarcinoma with different lymph node dissection ranges [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 401-404.
[6]	Zhiwen Ding, Yiming Zhao, Lu Wang. Progress in surgical and systematic treatment of intrahepatic cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 187-196.
[7]	Zhipeng Sun, Bin Shu, Liang Wang, Xin Huang, Pengfei Wang, Guangxin Li, Xiaojuan Wang, Gong Li, Shizhong Yang. Safety and efficacy of radiotherapy combined with targeted neoadjuvant immunotherapy for intrahepatic cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 92-96.
[8]	Chengshu Yu, Hongzhi Liu, Kecan Lin, Qizhu Lin, Tingfeng Huang, Weiping Zhou, Zhangjun Cheng, Jianying Lou, Shuguo Zheng, Xinyu Bi, Jianming Wang, Wei Guo, Fuyu Li, Jian Wang, Yamin Zheng, Jingdong Li, Shi Cheng, Yongyi Zeng. Risk factors of very early recurrence of intrahepatic cholangiocarcinoma after surgery [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 53-59.
[9]	Jingming Lu, Dawei Han, Yaoxing Ren, Tianxiao Huang, Junxi Xiang, Xufeng Zhang, Yi Lyu, Fumin Wang. Meta-analysis of lymph node metastasis prediction of intrahepatic cholangiocarcinoma based on preoperative radiomics [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 852-858.
[10]	Junhao Huang, Zongjie Chen, Tiansong Hu. Prognostic value of platelet-related parameters in intrahepatic cholangiocarcinoma patients undergoing radical resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(03): 308-312.
[11]	Mingzheng Chen, Yulong Li, Liukang Tang, Feng Xie. Research progress in IDH1 mutation in treatment of intrahepatic cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(01): 103-108.
[12]	Binkui Li. Conversion therapy for unresectable intrahepatic cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 511-516.
[13]	Chengyu Liao, Binhua Jiang, Long Huang, Danfeng Wang, Yifeng Tian, Shi Chen. Application value of modified three-step technique in laparoscopic radical resection of intrahepatic cholangiocarcinoma of left lobe [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(04): 395-400.
[14]	Facai Yang, Chuan You, Zhengqing Lei, Weinan Li, Anqi Duan, Yinghe Qiu, Jingdong Li, Zhangjun Cheng. Predictive value of tumor burden score combined with lymph node staging for postoperative survival of intrahepatic cholangiocarcinoma patients [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(04): 389-394.
[15]	Xiaopeng Yu, Chen Chen, Jialu Chen, Huanjun Tong, Yinghe Qiu, Hong Wu, Tianqiang Song, Yu He, Xianhai Mao, Wenlong Zhai, Zhangjun Cheng, Jingdong Li, Zhimin Geng, Zhaohui Tang. Preoperative clinicopathological features of patients obtaining survival benefit from lymph node dissection in intrahepatic cholangiocarcinoma resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(03): 278-283.

Please choose a citation manager

Content to export